Clinical Observation on the Efficacy of Metoprolol Sustained-Release Tablets Combined with Sacubitril Valsartan Tablets in the Treatment of Hypertension Complicated with Heart Failure
PANG Mingqun, et al
West District of Hefei First People's Hospital, Anhui Hefei 230031, China
Abstract：Objective: To explore the clinical efficacy of metoprolol succinate sustained-release tablets combined with sacubitril valsartan tablets in the treatment of hypertension complicated with heart failure. Methods: A total of 135 patients with hypertension complicated with heart failure admitted to our hospital from January 2020 to January 2023 were selected. According to the order of admission, they were divided into the Bisoprolol Group (odd numbers, conventional treatment + metoprolol sustained-release tablets) with 68 cases and the Sacubitril Group (even numbers, based on the Bisoprolol Group + sacubitril valsartan tablets) with 67 cases, using single and double numbers. The treatment effects, blood pressure, heart rate, cardiac function indicators, vascular endothelial function, and levels of cardiac troponin I (cTnI) and N-terminal pro-brain natriuretic peptide (NT-BNP) before and after treatment were compared between the two groups. Adverse reactions during the treatment period were recorded. Results: The total effective rate in the Sacubitril Group was higher than that in the Bisoprolol Group (97.01% vs 86.76%) (P<0.05). After treatment, both groups showed a significant reduction in systolic and diastolic blood pressure, heart rate, left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), endothelin (ET), cTnI, and NT-BNP (P<0.05). Left ventricular ejection fraction (LVEF), nitric oxide (NO), and calcitonin gene-related peptide (CGRP) increased (P<0.05). The differences before and after treatment between the two groups were statistically significant (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The combination of metoprolol sustained-release tablets and sacubitril valsartan sodium is significantly effective in treating hypertension with heart failure. This treatment can effectively control blood pressure, improve cardiac function and vascular endothelial function, and reduce levels of cTnI and NT-BNP. It is worthy of promotion and application in clinical practice.
庞明群, 方茹, 程永凤. 美托洛尔缓释片联合沙库巴曲缬沙坦钠片治疗高血压合并心衰患者临床疗效的观察[J]. 河北医学, 2023, 29(12): 2092-2097.
PANG Mingqun, et al. Clinical Observation on the Efficacy of Metoprolol Sustained-Release Tablets Combined with Sacubitril Valsartan Tablets in the Treatment of Hypertension Complicated with Heart Failure. HeBei Med, 2023, 29(12): 2092-2097.
2023, Vol. 29 
冀公网安备13080202000677号